Monomethyl fumarate treatment impairs maturation of human myeloid dendritic cells and their ability to activate T cells

Dimethyl fumarate (DMF) and its active metabolite monomethyl fumarate (MMF) effectively lead to reduction in disease relapses and active magnetic resonance imaging (MRI) lesions. DMF and MMF are known to be effective in modulating T- and B-cell responses; however, their effect on the phenotype and f...

Full description

Bibliographic Details

Published in:	Multiple sclerosis Vol. 25; no. 1; p. 63
Main Authors:	Mazzola, Maria Antonietta, Raheja, Radhika, Regev, Keren, Beynon, Vanessa, von Glehn, Felipe, Paul, Anu, Pierre, Isabelle, Kivisakk, Pia, Weiner, Howard L, Gandhi, Roopali
Format:	Journal Article
Language:	English
Published:	England 01.01.2019
Subjects:	Dendritic Cells - drug effects Dimethyl Fumarate - pharmacology Fumarates - pharmacology Humans Immunologic Factors - pharmacology Multiple Sclerosis, Relapsing-Remitting - blood Multiple Sclerosis, Relapsing-Remitting - drug therapy Myeloid Cells - drug effects T-Lymphocytes - drug effects co-stimulatory molecules Multiple sclerosis dimethyl fumarate myeloid dendritic cells monomethyl fumarate NF-kB
ISSN:	1477-0970, 1477-0970
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!